Inovio Pharmaceuticals, Inc. (INO)

Price$1.28

Value ScoreD

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-40.21%

Price vs S&P 500 (4W)14.12%

VGM Score18.40

Market Capitalization$107.78M

All Metrics

Book Value / Share (Quarterly)$0.09

P/TBV (Annual)1.19x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-81.47%

Cash Flow / Share (Quarterly)$-1.20

Price vs S&P 500 (YTD)-35.65%

Gross Margin (TTM)58.85%

Net Profit Margin (TTM)-25107.34%

EPS (TTM)$-1.70

10-Day Avg Trading Volume2.75M

EPS Excl Extra (TTM)$-1.70

Revenue Growth (5Y)-61.18%

EPS (Annual)$-1.81

ROI (Annual)-352.53%

Gross Margin (Annual)60.13%

Net Profit Margin (5Y Avg)-43066.73%

Cash / Share (Quarterly)$0.54

ROA (Last FY)-114.31%

Revenue Growth TTM (YoY)-69.99%

EBITD / Share (TTM)$-1.48

ROE (5Y Avg)-165.21%

Operating Margin (TTM)-27701.47%

Cash Flow / Share (Annual)$-1.29

P/B Ratio17.76x

P/B Ratio (Quarterly)19.91x

Net Income / Employee (Annual)$-758,400

EV / Revenue (TTM)287.92x

Net Interest Coverage (TTM)-43.65x

ROA (TTM)-129.81%

EPS Incl Extra (Annual)$-1.81

Current Ratio (Annual)1.40x

Quick Ratio (Quarterly)0.99x

3-Month Avg Trading Volume2.11M

52-Week Price Return-38.50%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$5.15

P/S Ratio (Annual)1649.49x

Asset Turnover (Annual)0.00x

52-Week High$2.98

Operating Margin (5Y Avg)-44274.27%

EPS Excl Extra (Annual)$-1.81

CapEx CAGR (5Y)-28.42%

Tangible BV CAGR (5Y)-2.96%

26-Week Price Return-24.28%

Quick Ratio (Annual)1.34x

13-Week Price Return-26.82%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.04x

Enterprise Value$81.51M

Revenue / Share Growth (5Y)-69.97%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-58.86%

Revenue / Employee (Annual)$600

Inventory Turnover (Annual)3.19x

Pretax Margin (Annual)-130005.97%

Cash / Share (Annual)$0.85

3-Month Return Std Dev89.76%

Gross Margin (5Y Avg)63.72%

Net Income / Employee (TTM)$-758,300

ROE (Last FY)-352.53%

Net Interest Coverage (Annual)-1.04x

EPS Basic Excl Extra (Annual)$-1.81

P/FCF (TTM)7.36x

Receivables Turnover (TTM)0.11x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.70

Receivables Turnover (Annual)0.11x

ROI (TTM)-201.57%

P/S Ratio (TTM)380.72x

Pretax Margin (5Y Avg)-43057.61%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.15

Price vs S&P 500 (52W)-66.70%

Year-to-Date Return-24.71%

5-Day Price Return-2.96%

EPS Normalized (Annual)$-1.81

ROA (5Y Avg)-85.92%

Net Profit Margin (Annual)-130005.97%

Month-to-Date Return16.96%

Cash Flow / Share (TTM)$-0.62

EBITD / Share (Annual)$-1.82

Operating Margin (Annual)-132877.43%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-160.03%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.70

P/TBV (Quarterly)1.19x

P/B Ratio (Annual)4.96x

Inventory Turnover (TTM)2.11x

Pretax Margin (TTM)-25107.34%

Book Value / Share (Annual)$0.35

Price vs S&P 500 (13W)-36.56%

Beta1.50x

Revenue / Share (TTM)$0.00

ROE (TTM)-201.57%

52-Week Low$1.03

vGradeD

gGradeF

mGradeD

vgmGradeF

Show chart for

Earnings Surprise History

Q1 26-0.28est. -0.35

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
INOInovio Pharmaceuticals, Inc.	D	F	D	$1.28
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies for HPV-associated diseases, cancer, and infectious diseases. The company's proprietary electroporation technology enables targeted delivery and enhanced immunogenicity of its DNA medicine candidates.